Premium
TU‐EF‐210‐00: Therapeutic Strategies and Image Guidance
Author(s) -
Payne Allison
Publication year - 2015
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.4925709
Subject(s) - medicine , therapeutic ultrasound , medical physics , high intensity focused ultrasound , ultrasound , radiology
The use of therapeutic ultrasound to provide targeted therapy is an active research area that has a broad application scope. The invited talks in this session will address currently implemented strategies and protocols for both hyperthermia and ablation applications using therapeutic ultrasound. The role of both ultrasound and MRI in the monitoring and assessment of these therapies will be explored in both pre‐clinical and clinical applications. Katherine Ferrara: High Intensity Focused Ultrasound, Drug Delivery, and Immunotherapy Rajiv Chopra: Translating Localized Doxorubicin Delivery to Pediatric Oncology using MRI‐guided HIFU Elisa Konofagou: Real‐time Ablation Monitoring and Lesion Quantification using Harmonic Motion Imaging Keyvan Farahani: AAPM Task Groups in Interventional Ultrasound Imaging and Therapy Learning Objectives: 1. Understand the role of ultrasound in localized drug delivery and the effects of immunotherapy when used in conjunction with ultrasound therapy. 2. Understand potential targeted drug delivery clinical applications including pediatric oncology. 3. Understand the technical requirements for performing targeted drug delivery. 4. Understand how radiation‐force approaches can be used to both monitor and assess high intensity focused ultrasound ablation therapy. 5. Understand the role of AAPM task groups in ultrasound imaging and therapies.Chopra: Funding from Cancer Prevention and Research Initiative of Texas (CPRIT), Award R1308 Evelyn and M.R. Hudson Foundation; Research Support from Research Contract with Philips Healthcare; COI are Co‐founder of FUS Instruments Inc Ferrara: Supported by NIH, UCDavis and California (CIRM and BHCE) Farahani: In‐kind research support from Philips Healthcare